Clinical Trials Logo

Brain Diseases clinical trials

View clinical trials related to Brain Diseases.

Filter by:

NCT ID: NCT01694953 Recruiting - Clinical trials for Mitochondrial NeuroGastroIntestinal Encephalopathy (MNGIE)

The Natural History Study of Mitochondrial NeuroGastroIntestinal Encephalopathy (MNGIE)

NAHIM
Start date: February 2013
Phase:
Study type: Observational

This is a multi-center natural history study of Mitochondrial NeurogastroIntestinal Encephalopathy (MNGIE). Patients will be followed over time to assess clinical symptoms. The investigators hope to learn more about the disease of MNGIE as well as develop useful measures of disease status for use in future clinical trials. Additional clinical centers will be listed as they become available.

NCT ID: NCT01683383 Completed - Clinical trials for Hypoxic Ischemic Encephalopathy

California Transport Cooling Trial

CTCT
Start date: September 2012
Phase: N/A
Study type: Interventional

Hypoxic ischemic encephalopathy (HIE) remains a major cause of death and severe disability despite advances in neonatal and perinatal medicine. Therapeutic hypothermia is the single most promising intervention for HIE. Reduction of brain temperature by 2° to 5°C has shown to be neuroprotective in newborn and adult animal models of brain ischemia. Therapeutic hypothermia instituted within 6 hours of birth has been shown to significantly improve survival and neurodevelopmental outcome in term newborns with HIE. Hypothermia is most effective if begun during the latent period, before the secondary energy failure. It is not known whether cooling initiated after 6 hours of age is effective. The goal of this proposal is to test the efficacy of the cooling device in achieving the target temperatures in patients with moderate to severe HIE during transport when compared with current practices.

NCT ID: NCT01662414 Completed - Parkinson Disease Clinical Trials

Effect of Undenatured Cysteine-Rich Whey Protein Isolate (HMS 90®) in Patients With Parkinson's Disease

Start date: April 2011
Phase: Phase 4
Study type: Interventional

This is a double-blind, placebo-controlled, Phase IV trial , comparing HMS 90® versus placebo (soy protein) as add-on (adjuvant) therapy in subjects with idiopathic Parkinson's Disease. The principal objective is to evaluate the changes in biomarkers of oxidative stress and,plasma amino acids, as well as improvement of clinical symptoms and brain function

NCT ID: NCT01649648 Completed - Clinical trials for Hypoxic Ischemic Encephalopathy

Autologous Cord Blood Cells for Brain Injury in Term Newborns

Start date: September 2011
Phase: Phase 1
Study type: Interventional

This is a pilot study to test feasibility and safety of collection, preparation and infusion of a baby's own (autologous) umbilical cord blood during the first 3 days of age if the baby is born with signs of brain injury. The cord blood used is fresh (not frozen and then thawed).

NCT ID: NCT01646619 Recruiting - Clinical trials for Severe Hypoxic Ischemic Encephalopathy

Efficacy Study of Hypothermia Plus Magnesium Sulphate(MgSO4) in the Management of Term and Near Term Babies With Hypoxic Ischemic Encephalopathy

MagCool
Start date: May 2012
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess whether the addition of a drug such as Magnesium sulphate while providing therapeutic hypothermia (or cooling) to babies who are asphyxiated at birth provides additional benefit to the babies' survival and outcome compared to cooling alone.

NCT ID: NCT01624311 Completed - Clinical trials for Urea Cycle Disorders

Pilot Study For Hypothermia Treatment In Hyperammonemic Encephalopathy In Neonates And Very Young Infants

Start date: August 2007
Phase: Phase 2
Study type: Interventional

This is a pilot study which will test the safety and feasibility of hypothermia treatment as adjunct therapy to conventional treatment of hyperammonemic encephalopathy (HAE) in neonates versus conventional treatment (dialysis, nutritional therapy, and ammonia scavenging drugs) only. The endpoint of the pilot study will be reached when either 24 patients have been enrolled and no serious adverse events were observed, when no patient has been enrolled in 5 years, or when serious adverse events occur which are clearly linked to the use of hypothermia. These would be serious complications not seen in patients on conventional therapy (dialysis , nutritional therapy, ammonia scavenging drugs) for HAE.

NCT ID: NCT01613417 Completed - Brain Disease Clinical Trials

Comparison of Prohance® With Gadovist®/Gadavistâ„¢ in Magnetic Resonance Imaging (MRI) of the Brain

TRUTH
Start date: August 2012
Phase: Phase 4
Study type: Interventional

This study aims at a direct comparison between ProHance (0.1 mmol/kg) and a validated comparator Gadovist/Gadavist (0.1 mmol/kg) in a crossover intra-individual design in subjects with brain tumors to confirm the identical overall technical and diagnostic performance of the two MR contrast agents.

NCT ID: NCT01603953 Completed - Cirrhosis Clinical Trials

Bioelectrical Impedance Vector Analysis in Cirrhotic Patients

BIVA
Start date: January 2009
Phase: N/A
Study type: Observational

Protein-energy malnutrition and muscle wasting are a common finding among patients with liver cirrhosis. Its prevalence may range from 50-90% depending on the methods used for nutritional assessment. Even stable cirrhotic patients referred as Child A have muscle depletion and the majority of patients classified as Child C have significant depletion. Malnutrition has been shown to be related to several complications of cirrhosis Despite the importance of nutritional status in patient's outcome, there is no gold standard for nutritional assessment. Traditional techniques used in healthy subjects to assess nutritional status cannot be used in cirrhotic patients due especially to ascites and peripheral edema, and altered rates of biochemical markers due to liver failure. Bioelectrical impedance vector analysis has emerged as a useful method to assess body composition and nutritional status especially in patients at the extremes of body weight (fluid overload, excess of adipose tissue, etc.). The aim of this study is to evaluate whether malnutrition assessed by bioelectrical impedance vector analysis is related to the development of hepatic encephalopathy

NCT ID: NCT01597102 Recruiting - Clinical trials for Cerebrovascular Disorders

Cerebrovascular Autoregulation During and After Liver Transplantation

dARICULtx
Start date: January 8, 2012
Phase:
Study type: Observational

The cerebrovascular autoregulation (AR) is impaired in patients with hepatic encephalopathy. Patients with the indication to liver transplantation mostly have mild to severe hepatic encephalopathy. Transplantation should recover the encephalopathy. The aim of the study is to investigate the AR during liver transplantation, with the questions if the AR is impaired at the beginning of surgery and if there are changes in AR. For follow up the AR will be measured at the first days after transplantation at the ICU.

NCT ID: NCT01559519 Completed - Clinical trials for Hepatic Encephalopathy

Post Transjugular Intrahepatic Portosystemic Shunt (Tips) Albumine Infusion to Prevent Hepatic Encephalopathy

Start date: September 2012
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the efficacy of albumin infusion to prevent post tips hepatic encephalopathy'